Elicio Therapeutics falls after mid-stage pancreatic cancer trial misses endpoint
ELTX tumbled after a mid-stage trial failed to show a meaningful improvement in progression-free survival for its pancreatic cancer therapy, missing the primary endpoint. The setback raises questions about the program's viability, funding needs, and strategic options. Investors will look for any data on secondary endpoints and next steps for the pipeline.
View signal analysis